Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S (ASND) Stock Price, Analysis & Data
| Bid | 232.11 |
| Market Cap | 16.32B |
| Revenue (ttm) | 1.05B |
| Net Income (ttm) | 741.76M |
| Beta | n/a |
| EPS (ttm) | 13.01 |
| PE Ratio (ttm) | 19.13 |
| Forward PE | 26.33 |
| P/B (ttm) | 9.82 |
| P/S (ttm) | 15.59 |
| Earnings Date | Apr 30, 2026 |
| Ask | 269.5 |
| Volume | 405,321 |
| Avg. Volume (20D) | 677,188 |
| Open | 246.55 |
| Previous Close | 247.40 |
| Day's Range | 246.47 - 253.55 |
| 52-Week Range | 186.05 - 282.15 |
| Analyst | Strong Buy |
| Price Target | 307.17 (23.44%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endo...
Financial Performance
In 2025, Ascendis Pharma A/S's revenue was 720.13M, an increase of 98.03% compared to the previous year's 363.64M. Earnings were -228.03M, a decrease of -39.69%.
Financial StatementsAnalyst Forecast
According to 18 analyst ratings, the average rating for ASND stock is "Strong Buy". The 12-month stock price forecast is 307.17, which is upside of 23.44% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
